Summary
The R644C variant of lamin A is controversial, as it has been linked to multiple phenotypes in familial studies, but has also been identified in apparently healthy volunteers. Here we present data from a large midwestern US cohort showing that this variant associates genetically with hepatic steatosis, and with related traits in additional publicly available datasets, while in vitro testing demonstrated that this variant increased cellular lipid droplet accumulation. Taken together, these data support this LMNA variant’s potential pathogenicity in lipodystrophy and metabolic liver disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by K08DK120948 (G.F.B.) and the University of Michigan Department of Internal Medicine. X.D., Y.C., and E.K.S. are supported in part by R01DK106621 (E.K.S.), R01DK107904 (E.K.S.), R01DK128871 (E.K.S.), R01DK131787 (E.K.S.), the University of Michigan Department of Internal Medicine, and a University of Michigan MBioFAR award.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of the University of Michigan gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Grant Support: This work was supported by K08DK120948 (G.F.B.) and the University of Michigan Department of Internal Medicine. X.D., Y.C., and E.K.S. are supported in part by R01DK106621 (E.K.S.), R01DK107904 (E.K.S.), R01DK128871 (E.K.S.), R01DK131787 (E.K.S.), the University of Michigan Department of Internal Medicine, and a University of Michigan MBioFAR award.
Disclosures: The authors declare no relevant disclosure(s).
Data Transparency: All relevant data are included within the manuscript and its accompanying supplementary material or are publicly available.
Data Availability
All relevant data are included within the manuscript and its accompanying supplementary material or are publicly available.